{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:58:19Z","timestamp":1793383099507,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK126978"],"award-info":[{"award-number":["R01DK126978"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["R01DK126978"],"award-info":[{"award-number":["R01DK126978"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Antiphospholipase A2 receptor antibody seropositivity by ELISA \u22652 and positive indirect immunofluorescence was optimal.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Noninvasive diagnosis of phospholipase A2 receptor\u2013associated membranous nephropathy among patients with proteinuria is feasible using both assays.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical practice guidelines recommend that a kidney biopsy is no longer required to confirm a diagnosis of membranous nephropathy (MN) in patients with nephrotic syndrome and a positive test for antiphospholipase A2 receptor antibodies (PLA2R-Ab). However, the optimal diagnostic strategy for using the PLA2R-Ab ELISA, PLA2R-Ab indirect immunofluorescence (IIF) test, and genetic risk score (GRS) for diagnosing MN, including the tests' optimal thresholds for positivity among incident patients with proteinuria, is still unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used serum samples at or before the first clinically indicated kidney biopsy from participants in the Nephrotic Syndrome Study Network to analyze test performance characteristics using different combinations and cutoffs of the PLA2R-Ab ELISA, IIF, and GRS for diagnosing MN. Secondary analyses included serum samples within 6 months after biopsy but before any immunosuppression use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 325 study participants with serum samples available on or before the day of kidney biopsy and an additional 143 study participants with samples within 6 months after biopsy but before any immunosuppression use. Of these participants, 26% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =85) had biopsy-confirmed MN. The combination of ELISA \u22652 RU\/ml and positive IIF was the optimal approach, with sensitivity of 0.60, specificity of 1.00, negative predictive value of 0.92, and positive predictive value of 1.00. Using IIF to confirm only borderline ELISA titers between 2 and 20 RU\/ml resulted in similar sensitivity but specificity of &gt;0.99. In our multiethnic study sample, we did not find improved diagnostic performance with the addition of GRSs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the Nephrotic Syndrome Study Network cohort, combined PLA2R-Ab testing with ELISA and IIF provided optimal test characteristics in making a noninvasive diagnosis of MN before or soon after kidney biopsy, including in patients with subnephrotic proteinuria. Further studies in multiethnic populations are needed to assess whether genetic data can augment this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000000671","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T12:03:52Z","timestamp":1740744232000},"page":"697-705","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Noninvasive Diagnostic Strategies for Membranous Nephropathy in the Nephrotic Syndrome Study Network"],"prefix":"10.2215","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-1160","authenticated-orcid":false,"given":"Jarcy","family":"Zee","sequence":"first","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania"},{"name":"Cabaletta Bio, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8672-2166","authenticated-orcid":false,"given":"Ahmed","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-9669","authenticated-orcid":false,"given":"Lili","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5047-6715","authenticated-orcid":false,"given":"Krzysztof","family":"Kiryluk","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-4089","authenticated-orcid":false,"given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"1","key":"B1-20250512","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"issue":"5","key":"B2-20250512","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.kint.2019.10.022","article-title":"A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients","volume":"97","author":"Meyer-Schwesinger","year":"2020","journal-title":"Kidney Int."},{"issue":"3","key":"B3-20250512","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","article-title":"Pathogenicity of human anti-PLA 2 R1 antibodies in minipigs: a pilot study","volume":"34","author":"Reinhard","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B5-20250512","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ekir.2019.11.008","article-title":"Development of a standardized chemiluminescence immunoassay for the detection of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"5","author":"D\u00e4hnrich","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B6-20250512","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int."},{"issue":"12","key":"B7-20250512","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2215\/CJN.05480421","article-title":"Noninvasive diagnosis of pla2r-associated membranous nephropathy: a validation study","volume":"16","author":"Bobart","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4S","key":"B8-20250512","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"issue":"9","key":"B9-20250512","doi-asserted-by":"crossref","first-page":"890","DOI":"10.34067\/KID.0003262020","article-title":"Kidney biopsy is required for nephrotic syndrome with PLA2R+ and normal kidney function: the con view","volume":"1","author":"Bobart","year":"2020","journal-title":"Kidney360."},{"issue":"9","key":"B10-20250512","doi-asserted-by":"crossref","first-page":"887","DOI":"10.34067\/KID.0003752020","article-title":"Kidney biopsy is required for nephrotic syndrome with PLA2R+ and normal kidney function: pro","volume":"1","author":"Hogan","year":"2020","journal-title":"Kidney360."},{"issue":"9","key":"B11-20250512","doi-asserted-by":"crossref","first-page":"894","DOI":"10.34067\/KID.0004012020","article-title":"Kidney biopsy is required for nephrotic syndrome with PLA2R+ and normal kidney function: commentary","volume":"1","author":"Glassock","year":"2020","journal-title":"Kidney360."},{"issue":"1","key":"B12-20250512","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun."},{"issue":"5","key":"B13-20250512","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2215\/CJN.0000000000000422","article-title":"Combined serologic and genetic risk score and prognostication of phospholipase A2 receptor-associated membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B14-20250512","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the nephrotic syndrome study network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int."},{"issue":"4","key":"B15-20250512","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.kint.2020.10.047","article-title":"Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease","volume":"99","author":"Pierce","year":"2021","journal-title":"Kidney Int."},{"issue":"19","key":"B16-20250512","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med."},{"issue":"2","key":"B17-20250512","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ajhg.2018.07.004","article-title":"An eQTL landscape of kidney tissue in human nephrotic syndrome","volume":"103","author":"Gillies","year":"2018","journal-title":"Am J Hum Genet."},{"issue":"7571","key":"B18-20250512","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature."},{"issue":"2","key":"B19-20250512","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.kint.2022.09.011","article-title":"False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy","volume":"103","author":"Hoxha","year":"2023","journal-title":"Kidney Int."},{"issue":"2","key":"B20-20250512","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.kint.2022.11.004","article-title":"False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int."},{"issue":"2","key":"B21-20250512","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.kint.2018.11.016","article-title":"Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int."},{"issue":"12","key":"B22-20250512","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2215\/CJN.11180821","article-title":"Time to abandon kidney biopsy to diagnose membranous nephropathy?","volume":"16","author":"Ronco","year":"2021","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"B23-20250512","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41379-019-0267-z","article-title":"Diagnostic role of renal biopsy in PLA2R1-antibody-positive patients with nephrotic syndrome","volume":"32","author":"Wiech","year":"2019","journal-title":"Mod Pathol."},{"issue":"3","key":"B24-20250512","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.kint.2020.08.039","article-title":"Rationale and design of the kidney precision medicine Project","volume":"99","author":"De Boer","year":"2021","journal-title":"Kidney Int."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:47Z","timestamp":1786369367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000671","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2024-05-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}